ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 12,500 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott sold 12,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $16.00, for a total value of $200,000.00. Following the transaction, the chief financial officer now owns 4,949 shares of the company’s stock, valued at approximately $79,184. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY opened at $16.13 on Friday. ARS Pharmaceuticals, Inc. has a 12 month low of $3.35 and a 12 month high of $16.89. The stock’s fifty day moving average price is $13.51 and its 200-day moving average price is $10.76.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts forecast that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SPRY. nVerses Capital LLC bought a new position in ARS Pharmaceuticals in the third quarter valued at about $30,000. Russell Investments Group Ltd. bought a new position in ARS Pharmaceuticals in the first quarter valued at about $60,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares during the period. Principal Financial Group Inc. bought a new position in ARS Pharmaceuticals in the second quarter valued at about $87,000. Finally, Paloma Partners Management Co bought a new position in ARS Pharmaceuticals in the first quarter valued at about $103,000. Institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SPRY. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Leerink Partners increased their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $24.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.